Compare Bristol-Myers Squibb Co (BMY) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Keysight Technologies Inc — how do they compare? Bristol-Myers Squibb Co trades at $57.13 (market cap $116.30B), while Keysight Technologies Inc trades at $325.73 (market cap $55.67B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.1× Keysight Technologies Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals.
| BMY | KEYS | |
|---|---|---|
Market Cap | $116.30B | $55.67B |
Sector | Health | Technology |
52-Week High | $62.37 | $373.34 |
52-Week Low | $42.60 | $158.51 |
Enterprise Value | $152.24B | $56.01B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Keysight Technologies (KEYS) trades at $320.83, down 0.38% today, with technical indicators showing a bearish trend near key support at $317. The company reported strong Q1 2026 earnings of $2.87 per share, beating estimates of $2.32, and maintains robust profitability with a 17.31% net income margin. Recent news highlights product launches in network cybersecurity and photonics design, supporting growth in AI and 5G markets.
Wall Street maintains a bullish outlook with a $396.56 consensus price target and 75% buy ratings, though high valuation multiples and volatile cash flows pose risks. Upside potential hinges on execution in high-growth tech sectors, while investor sentiment is tempered by near-term technical weakness and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
